To meet the oxygen demand of cells a stable pO2 control is an essential part of every cultivation. The objective of this application note is to demonstrate the performance of a new generation of mass flow controllers in the BIOSTAT® B-DCU bioreactor system. Several comparative cell cultivations were performed.
Ensuring that the cells do not have too much or too little, enables them to grow fast and maximize the product secretion. Within this application is an example method on how to establish glucose feed control is documented and as well as highlighting the key benefits of applying this method to other processes.
Challenges of T cell immunotherapies include the costly manufacturing process relying on lengthy and complex open workflows with high manual labor requirements that influence product variability. This application note describes the details of a robust CAR T cell manufacturing workflow that can be adapted for cGMP compliance in commercial production of CAR T cells.
This study presents how strategic enhancements to the sparge and agitation systems of Thermo Scientific HyPerforma S.U.B.s have revealed the potential for a three- to four-fold improvement in mixing and mass transfer performance compared to legacy S.U.B. designs.
Learn how a structured 3-step approach can help overcome the challenge of molecular characterization and a limited budget.
How SYLOID FP silica products contribute significantly in mitigating/resolving key challenges such as formulation stability over time and their ability to withstand challenging processing conditions.
The combined adsorption capacity, porosity, particle size, and density of the SYLOID® XDP silicas provide a tool to convert liquid ingredients into free flowing powder.
Grace’s SYLOID® 244 FP silica is highly porous and an excellent solution for converting viscous Simethicone into compressible free flowing powder to make chewable tablets.
SYLOID® FP and XDP silicas excipients are micronized synthetic amorphous silica gels of high purity which are widely formulated into many pharmaceutical products.
This moisture activated dry granulation (MADG) technique provides a way to address common problems such as endpoint detection, drying, and milling with an efficient, cost-effective granulating process.
|
|
|
|
|
|
|
|
|